The South San Francisco-based company, which will trade under the MAZE symbol, should also see trading start today. The two have gone public just a few days after China's Ascentage Pharma claimed ...

Maze Therapeutics (MAZE), which is developing treatments for chronic kidney disease, has filed to raise $100M through an initial public offering. While the company didn't disclose terms in its SEC ...